JPMorgan Chase & Co. Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price

iTeos Therapeutics (NASDAQ:ITOS) had its price objective dropped by stock analysts at JPMorgan Chase & Co. from $22.00 to $15.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 112.77% from the stock’s current price.

Other analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Thursday. Wells Fargo & Company dropped their price target on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Finally, Wedbush restated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday.

iTeos Therapeutics Stock Down 0.6 %

iTeos Therapeutics stock opened at $7.05 on Thursday. The firm has a 50-day moving average price of $7.52 and a two-hundred day moving average price of $9.48. The firm has a market capitalization of $257.56 million, a price-to-earnings ratio of -2.24 and a beta of 1.38. iTeos Therapeutics has a 52-week low of $6.67 and a 52-week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13. Research analysts expect that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio raised its holdings in shares of iTeos Therapeutics by 192.2% in the 4th quarter. Public Employees Retirement System of Ohio now owns 84,220 shares of the company’s stock worth $647,000 after purchasing an additional 55,394 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in shares of iTeos Therapeutics by 266.7% in the 4th quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock worth $845,000 after purchasing an additional 80,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of iTeos Therapeutics in the 4th quarter worth approximately $42,000. Man Group plc raised its holdings in shares of iTeos Therapeutics by 34.7% in the 4th quarter. Man Group plc now owns 29,169 shares of the company’s stock worth $224,000 after purchasing an additional 7,516 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of iTeos Therapeutics by 90.5% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,589 shares of the company’s stock worth $965,000 after purchasing an additional 59,649 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.